Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07584733 | Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | Phase 2 | 50 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07231809 | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients(HIVEC) | not yet recruiting | N/A | 50 | AC.TA. S.r.l.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07557563 | Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial(CALCIFER) | not yet recruiting | Phase 1 | 20 | Juan Luis VásquezOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07504939 | Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | — | 36 | Peking University First HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07529639 | Tumor Budding and T1 Substaging in Urothelial Bladder Cancer | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT07525349 | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07526792 | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | not yet recruiting | Phase 3 | 406 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | not yet recruiting | Phase 1 | 21 | UTC Therapeutics Inc.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma | not yet recruiting | N/A | 43 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | not yet recruiting | N/A | 174 | Sun Yat-sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 2 | 27 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07465458 | Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients(RASROP-003) | not yet recruiting | — | 226 | Humanitas Hospital, ItalyOTHER | 2 | Mar 16, 2026 | clinicaltrials |
| NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment(PRELUDE) | not yet recruiting | Phase 2 | 108 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07460245 | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma(AVESEC) | not yet recruiting | Phase 2 | 144 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07445308 | The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. | not yet recruiting | Phase 1 / Phase 2 | 120 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 0 | Mar 3, 2026 | clinicaltrials |
| NCT07243067 | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer | not yet recruiting | — | 300 | Mayo ClinicOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07412171 | NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC(NECTAR) | not yet recruiting | Phase 2 | 40 | Peking University Third HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07374549 | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 100 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07351266 | Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors | not yet recruiting | — | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma(RUBIKID) | not yet recruiting | Phase 2 | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07324876 | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) | not yet recruiting | — | 860 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07233668 | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC(IVE in mRCC) | not yet recruiting | N/A | 172 | Seoul National University HospitalOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06994078 | Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors | not yet recruiting | N/A | 56 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06982690 | Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial | not yet recruiting | N/A | 370 | National Taiwan University HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06960174 | Virtual Renality: Assessing the Impact of Virtual Reality on Preoperative Planning in Renal Cancer Surgery | not yet recruiting | N/A | 70 | St. Antonius HospitalOTHER | 0 | May 7, 2025 | clinicaltrials |
| NCT06870279 | A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC | not yet recruiting | Phase 1 | 28 | RenJi HospitalOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06912672 | Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma(UMT-UC) | not yet recruiting | — | 1,500 | Shanghai Epiprobe Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 8, 2025 | clinicaltrials |
| NCT06798246 | HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study | not yet recruiting | — | 200 | Peking University First HospitalOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT06773377 | Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma | not yet recruiting | — | 77 | Assiut UniversityOTHER | 0 | Jan 14, 2025 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06585878 | A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma | not yet recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06574412 | Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2026source: clinicaltrials